Nanette D.
- Country
- Denmark
- Department
- Department of Pediatrics
Research Overview
- Randomized, Double-Blind, Placebo-Controlled Trial of Galcanezumab in Adolescents Aged 12-17 with Chronic Migraine: REBUILD-2 Study
- Randomized, Double-Blind, Placebo-Controlled Trial of Galcanezumab for Preventive Treatment of Episodic Migraine in Pediatric Patients Aged 6-17 Years
- Phase III Study on Immunogenicity and Safety of MenACYW Conjugate Vaccine Versus Nimenrix in Healthy Infants and Toddlers
Data & Insights
Has run more than one trial at 20 of 80 partner sites.
Specializations
Pediatric Neurology
This investigator specializes in treating neurological conditions in young patients, with particular emphasis on pediatric migraine management. Their research encompasses both episodic and chronic migraine treatments for children and adolescents aged 6-17 years.
- Episodic Migraine Prevention
- Chronic Migraine Treatment
- Pediatric Migraine Therapeutics
The investigator's work focuses on evaluating novel therapeutic approaches for migraine prevention in young populations.
Movement Disorders
The investigator conducts research in neurological movement disorders, with particular expertise in treating Tourette's Disorder across different age groups, from children to adults.
- Pediatric Tourette's Treatment
- Adolescent Neurological Care
- Long-term Movement Disorder Management
Their research extends to investigating therapeutic interventions for movement disorders in diverse age groups.
Preventive Medicine
The investigator's work includes preventive medicine with a focus on meningococcal disease prevention in infants and toddlers through immunization studies.
- Vaccine Immunogenicity
- Infant Immunization
- Preventive Healthcare
Their research contributes to advancing preventive strategies in pediatric infectious diseases.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.